Oligoclonal antibody
Oligoclonal antibodies are an emerging immunological treatment relying on the combinatory use of several monoclonal antibodies (mAb) in one single drug.[1] The composition can be made of mAb targeting different epitopes of a same protein (homo-combination) or mAb targeting different proteins (hetero-combination). It mimicks the natural polyclonal humoral immunological response to get better efficiency of the treatment. This strategy is most efficient in infections and in cancer treatment as it allow to overcome acquired resistance by pathogens and the plasticity of cancers.[2]
History
[edit]Oligoclonal antibody treatment is a part of the serotherapy strategy (or antiserum).
19th century: Serotherapy was initiated thanks to Shibasaburo Kitasato and Emil von Behring in Germany, and Emile Roux in France. It is the administration of animal or human serum that was previously exposed to a pathogen and thus contains antibodies against it and will help the patient to fight infection.[2]
1975 and 1986: First mAb was produced by hybridomas technique and then fully licensed. It was great progress since it allows targeting of specific epitope that can be shared among several diseases.[3]
1982: Combination of two antibodies to enhance the immune response against viruses.
2000's: Several research teams came up with the idea of combining antibodies against different epitopes of the same receptor in cancer treatment. Particularly in anti-EGFR, anti-HER2 or anti-cMET combinations.
2010: Combination of two antibodies against immune control checkpoint to enhance cytotoxic T lymphocytes response and inhibit regulatory T lymphocytes suppressive effect on the immune response. [2]
2012: First oligoclonal antibody combination was approved for use. It is composed of trastuzumab and pertuzumab both targeting HER-2 in breast cancer.[2]
Numerous studies on animal models or in clinical trials are currently ongoing for treatment of infections and cancers.[2][4]
Infectious diseases treatment
[edit]In infection oligoclonal treatment may be used to directly target the pathogen (e.g. surface marker on viruses[5] or bacterias) or to neutralize toxins (e.g. botulinum neurotoxins,[6] Clostridioides difficile toxins[7]).
Many pathogens show increasing resistance to currently available drugs, especially antibiotics. This is particularly true for bacteria, but they harbor many membrane surface markers that can be targeted by antibodies. Oligoclonal treatment is recognized to have the potential to address this issue by aiming for multiple surface proteins and still can bind to proteins after mutation even if the affinity is lowered. However, most of these treatments are still in the stage of clinical trials.[1]
Oncologic treatment
[edit]In cancer treatment, several targets and strategies can be used:[4]
- Targeting cancer cell markers (e.g. mutated EGFR, HER2): it raises antibody-dependent cell-mediated cytotoxicity (ADCC) response against tumor cells.
- Targeting secreted signaling proteins of tumoral environment (e.g. VEGF neutralization) : limiting tumor environment, for example blocking angiogenesis.
- Targeting immune cells regulation checkpoints : inhibition of T regulatory cells downregulatory effects (e.g. using antagonist against CTLA-4) , activation of cytotoxic T cells (e.g. using antagonist against PD-1). The goal is to activate the immune cells by lifting self-tolerance checkpoints that are restraining T cells to attack tumor cells.
Today, more than 300 antibody combinations are undergoing phase II or phase III clinical trials for various targets and cancer types (both solid and liquid). Most of them are targeting immune checkpoints (CTLA-4, PD1/PD-L1, ...) [4]. The only oligoclonal antibody treatment against immune checkpoint currently approved is the cocktail of nivolumab (anti-PD1 antibody) and ipilimumab (anti-CTLA-4 antibody). It is used to treat melanomas,[8] low-risk renal cancer and colorectal cancer.[4] This combination is also on phase III clinical trial to be used to treat non-small lung cancer, it shows good efficacy.[9]
Treatments on non-small lung cancer have shown higher efficiency on patient with tumors of heavy mutational background. This underlines the potential of oligoclonal treatments to tackle cancer plasticity.[10]
See also
[edit]References
[edit]- ^ a b Corti, Davide; Kearns, Jeffrey D (23 March 2016). "Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease". Current Opinion in Immunology. 40: 51–61. doi:10.1016/j.coi.2016.03.001. PMC 7127534. PMID 26995095.
- ^ a b c d e Labouret, C; Poul, MA; Chardès, T (1 December 2019). "[Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures]". Médecine/Sciences. 35 (12): 1083–1091. doi:10.1051/medsci/2019216. PMID 31903921. S2CID 213457290.
- ^ Liu, Justin K.H. (13 August 2014). "The history of monoclonal antibody development e Progress, remaining challenges and future innovations". Annals of Medicine and Surgery. 3 (4): 113–116. doi:10.1016/j.amsu.2014.09.001. PMC 4284445. PMID 25568796.
- ^ a b c d Christel Larbouret ,Laurent Gros ,André Pèlegrin and Thierry Chardès (15 September 2021). "Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures". Cancers. 13 (18): 4620. doi:10.3390/cancers13184620. PMC 8465647. PMID 34572847.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Yotam Bar-On, Henning Gruell, Till Schoofs, Joy A Pai, Lilian Nogueira, Allison L Butler, Katrina Millard, Clara Lehmann, Isabelle Suárez, Thiago Y Oliveira, Theodora Karagounis, Yehuda Z Cohen, Christoph Wyen, Stefan Scholten, Lisa Handl, Shiraz Belblidia, Juan P Dizon, Jörg J Vehreschild, Maggi Witmer-Pack, Irina Shimeliovich, Kanika Jain, Kerstin Fiddike, Kelly E Seaton, Nicole L Yates, Jill Horowitz, Roy M Gulick, Nico Pfeifer, Georgia D Tomaras, Michael S Seaman, Gerd Fätkenheuer, Marina Caskey, Florian Klein , Michel C Nussenzweig (26 September 2018). "Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals". Nature Medicine. 24 (11): 1701–1707. doi:10.1038/s41591-018-0186-4. PMC 6221973. PMID 30258217.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Yongfeng Fan, Consuelo Garcia-Rodriguez, Jianlong Lou, Weihua Wen, Fraser Conrad, Wenwu Zhai, Theresa J. Smith, Leonard A. Smith and James D. Marks1 (21 March 2017). "A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes". PLOS ONE. 12 (3): e0174187. Bibcode:2017PLoSO..1274187F. doi:10.1371/journal.pone.0174187. PMC 5360321. PMID 28323873.
{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link) - ^ Andre J. Marozsan, Dangshe Ma, Kirsten A. Nagashima, Brian J. Kennedy, Yun (Kenneth) Kang, Robert R. Arrigale, Gerald P. Donovan, Wells W. Magargal, Paul J. Maddon, William C. Olson (25 June 2012). "Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies". The Journal of Infectious Diseases.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Frank Stephen Hodi, Vanna Chiarion-Sileni, Prof Rene Gonzalez, Prof Jean-Jacques Grob, Prof Piotr Rutkowski, Charles Lance Cowey, and al. (2018). "Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial". The Lancet Oncology. 19 (11): 1480–1492. doi:10.1016/S1470-2045(18)30700-9. PMID 30361170. S2CID 53103953.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Reck, Martin; Borghaei, Hossein; J O'Byrne, Kenneth (8 May 2019). "Nivolumab plus ipilimumab in non-small-cell lung cancer". Future Medicine. 15 (19): 2287–2302. doi:10.2217/fon-2019-0031. hdl:2262/89339. PMID 31066582. S2CID 147707142.
- ^ A Rivzi, Naiyer (12 March 2015). "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer". Science. 348 (6230): 124–128. Bibcode:2015Sci...348..124R. doi:10.1126/science.aaa1348. PMC 4993154. PMID 25765070.